Atara Biotherap (ATRA)

$15.59 +1.10 (7.59%)
Market Cap 101.76M
Revenue (ttm) 128.94M
Net Income (ttm) -85.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 8.21
Profit Margin -66.23%
Debt to Equity Ratio 0.00
Volume 51,100
Avg Vol 55,066
Day's Range N/A - N/A
Shares Out 7.02M
Stochastic %K 69%
Beta 0.25
Analysts Sell
Price Target $13.33

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
takingstock73
takingstock73 Oct. 26 at 12:31 PM
$ATRA 76 Days til Jan 10 and counting
0 · Reply
Smurfologist
Smurfologist Oct. 21 at 6:14 PM
$ATRA Why say anything when $ATRA is doing tha damn thang?!? I'm gonna just let the stock do its thang and keep speaking loudly by gradually raising its stock price!!! And, if $ATRA beat its quarterly earnings for the 4th time in a row......¡Mios Dios! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
takingstock73
takingstock73 Oct. 20 at 7:46 PM
$ATRA let's go
0 · Reply
chinchinbull
chinchinbull Oct. 17 at 8:26 PM
After hours runner $AKAN $NEOV $ATRA $TGHL
2 · Reply
ninergizer
ninergizer Oct. 16 at 1:47 PM
$PRAX $ATRA could be next. Do your DD. Tab-cel® (Atara) — EBV+ PTLD after transplant PDUFA: Jan 10, 2026 Why FDA likely to approve: Patients with EBV+ PTLD post-transplant have no approved therapies. Tab-cel demonstrated durable responses in pivotal data; CRL in Jan 2025 was mainly CMC/inspection-related, not efficacy/safety. Resubmission accepted with Priority Review. Public health urgency: Immunocompromised patients with very high mortality risk.
1 · Reply
takingstock73
takingstock73 Oct. 15 at 3:51 PM
$ATRA this is just the beginning. Sale or seeing through to Jan 10 , either way will be a huge win.
0 · Reply
Dimon11
Dimon11 Oct. 15 at 12:21 PM
$ATRA i see here on stockwits atra has a bearish sentiment... Hmm, the company is being getting ready to be sold! CEO has recently bought hell of shares in the open market.... That would be interesting.
1 · Reply
hassle
hassle Oct. 8 at 1:01 PM
$ATRA is there some positive news?
3 · Reply
Doozio
Doozio Oct. 7 at 4:41 PM
$ATRA faaatch 💣 or…..
0 · Reply
Smurfologist
Smurfologist Oct. 7 at 4:22 PM
$ATRA is over $15.00?!? UNREAL!!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
Latest News on ATRA
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 4 weeks ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB CORT

Atara Biotherapeutics Announces Changes to Its Board of Directors

Sep 3, 2025, 6:00 PM EDT - 7 weeks ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:57 AM EDT - 3 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 24, 2025, 8:00 AM EDT - 3 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 15, 2025, 8:00 AM EDT - 3 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jul 14, 2025, 8:00 AM EDT - 3 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025, 8:50 PM EDT - 5 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:35 AM EDT - 5 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 5 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025, 5:06 PM EDT - 6 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 4:01 PM EST - 8 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 8 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 14, 2025, 8:11 AM EST - 9 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 9 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 9, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:01 PM EST - 9 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 7, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 6, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 5, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 4, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 3, 2025, 7:00 AM EST - 9 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 30, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 29, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 7:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 28, 2025, 3:23 AM EST - 9 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 27, 2025, 8:30 PM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 1:11 PM EST - 9 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 7:30 AM EST - 9 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 21, 2025, 12:21 AM EST - 10 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:41 AM EST - 10 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Jan 16, 2025, 8:30 AM EST - 10 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

takingstock73
takingstock73 Oct. 26 at 12:31 PM
$ATRA 76 Days til Jan 10 and counting
0 · Reply
Smurfologist
Smurfologist Oct. 21 at 6:14 PM
$ATRA Why say anything when $ATRA is doing tha damn thang?!? I'm gonna just let the stock do its thang and keep speaking loudly by gradually raising its stock price!!! And, if $ATRA beat its quarterly earnings for the 4th time in a row......¡Mios Dios! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
takingstock73
takingstock73 Oct. 20 at 7:46 PM
$ATRA let's go
0 · Reply
chinchinbull
chinchinbull Oct. 17 at 8:26 PM
After hours runner $AKAN $NEOV $ATRA $TGHL
2 · Reply
ninergizer
ninergizer Oct. 16 at 1:47 PM
$PRAX $ATRA could be next. Do your DD. Tab-cel® (Atara) — EBV+ PTLD after transplant PDUFA: Jan 10, 2026 Why FDA likely to approve: Patients with EBV+ PTLD post-transplant have no approved therapies. Tab-cel demonstrated durable responses in pivotal data; CRL in Jan 2025 was mainly CMC/inspection-related, not efficacy/safety. Resubmission accepted with Priority Review. Public health urgency: Immunocompromised patients with very high mortality risk.
1 · Reply
takingstock73
takingstock73 Oct. 15 at 3:51 PM
$ATRA this is just the beginning. Sale or seeing through to Jan 10 , either way will be a huge win.
0 · Reply
Dimon11
Dimon11 Oct. 15 at 12:21 PM
$ATRA i see here on stockwits atra has a bearish sentiment... Hmm, the company is being getting ready to be sold! CEO has recently bought hell of shares in the open market.... That would be interesting.
1 · Reply
hassle
hassle Oct. 8 at 1:01 PM
$ATRA is there some positive news?
3 · Reply
Doozio
Doozio Oct. 7 at 4:41 PM
$ATRA faaatch 💣 or…..
0 · Reply
Smurfologist
Smurfologist Oct. 7 at 4:22 PM
$ATRA is over $15.00?!? UNREAL!!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
takingstock73
takingstock73 Oct. 7 at 3:20 PM
$ATRA almost hit 15
0 · Reply
ninergizer
ninergizer Oct. 3 at 7:14 PM
$ATRA Great entry here. Starting a new position until PDUFA, still low next 3 months run up. Do your DD always. PDUFA: Jan 10, 2026 Tab-cel® (Atara) — Allogeneic T-cell therapy for EBV+ PTLD FDA Likelihood: High (Priority Review, CRL was CMC/inspection). Market Impact: Small population, but ultra-high unmet need. EBV+ PTLD is rare, but mortality is >80% untreated. Orphan pricing likely (>$200K/course). Potential: could bring $200–300M annually plus pave path for allogeneic T-cell therapies.
1 · Reply
takingstock73
takingstock73 Sep. 30 at 9:27 PM
$ATRA do I hear 15 ?
0 · Reply
Doozio
Doozio Sep. 27 at 2:58 PM
$ATRA 🧠 is on the outside with those weekly closes 🐒🍌🧠⏰♾️
0 · Reply
shoagh12
shoagh12 Sep. 25 at 11:56 AM
$ATRA
0 · Reply
hassle
hassle Sep. 24 at 8:04 PM
$ATRA No news, but up and up. Must be good revenue for Q3 than expected.
1 · Reply
takingstock73
takingstock73 Sep. 24 at 4:39 PM
$ATRA let's go
0 · Reply
shoagh12
shoagh12 Sep. 24 at 3:16 PM
$ATRA
0 · Reply
JazzyJ03
JazzyJ03 Sep. 24 at 3:14 PM
$ATRA
0 · Reply
Smurfologist
Smurfologist Sep. 24 at 2:47 PM
$ATRA has beat the last 3 reporting quarters STRAIGHT; let's see if they will beat in the 3rd quarter.......LET'S GO, DAMN IT!!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
Smurfologist
Smurfologist Sep. 24 at 2:43 PM
$ATRA is lookin' good rat now......CONGRATS TO THE LONGS and thanks for slappin' them SHORTS in dey mouf HARD!!! DO DAT $HIT, $ATRA!!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
Smurfologist
Smurfologist Sep. 24 at 2:37 PM
$ATRA, YOU ARE A MONSTA!!!!! GIT IT, GURL!!!!! KAAAAAAAAAAAAAAABOOOOOOOOOOOOOOOM🙏🏾💪🏾🐃💣💥🚀
0 · Reply